/
AQST
$4.16-$0.23 (-5.24%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$550.7M
125M shares
52-week range
$2.93 – $7.55
27% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.70%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$0.19
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $67.4M | $52.6M | $45.8M | $50.8M | $47.7M | $50.6M | $57.6M | $44.5M |
| Cost of revenue | $21.0M | $20.4M | $13.0M | $15.0M | $19.4M | $20.8M | $17.9M | $17.2M |
| Gross profit | $46.4M | $32.2M | $32.9M | $35.8M | $28.3M | $29.8M | $39.7M | $27.4M |
| Gross margin | 68.9% | 61.3% | 71.7% | 70.5% | 59.3% | 58.8% | 69.0% | 61.5% |
| R&D | $23.1M | $20.6M | $19.9M | $17.0M | $17.5M | $13.1M | $20.3M | $17.2M |
| Operating income | −$48.9M | −$52.7M | −$42.9M | −$34.7M | −$42.1M | −$15.1M | −$30.8M | −$69.7M |
| EBITDA | −$50.3M | −$53.9M | −$39.2M | −$45.1M | −$39.6M | $1.2M | −$26.6M | −$66.1M |
| Net income | −$61.4M | −$66.2M | −$55.8M | −$70.5M | −$54.4M | −$7.9M | −$44.1M | −$83.8M |
| Net margin | -91.0% | -125.9% | -121.7% | -138.8% | -114.1% | -15.6% | -76.7% | -188.1% |
| EPS (diluted) | -2.96 | -2.87 | -1.66 | -1.85 | -1.12 | -0.13 | -0.51 | -0.76 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $51M | $-0.41 | $-0.51–$-0.24 | 4 |
| 2027 | $72M | $-0.38 | $-0.56–$-0.10 | 3 |
| 2028 | $101M | $-0.29 | $-0.46–$0.01 | 3 |
| 2029 | $169M | $-0.03 | $-0.04–$-0.02 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Aquestive Therapeutics, Inc. Common Stock
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
www.aquestive.com- Employees
- 147
- IPO / List date
- Jul 25, 2018
- HQ
- WARREN, NJ
Held by traders on TradeandTell
No one on the platform currently holds AQST.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 414,400 | $2.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AQST yet.
